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Introtluction
In the routine checking of patients under anticoagulant treatment a discrepancy
has frequentlybeen observed between the results of various clotting assays. Study of
the published data onthe clotting factor levelsinlong-term anticoagulant, treatment
shoris that accord.ing to some authors the four vitamin K-dependen-t clotting factors
(i. e. factors II, VII, IX, and X) drop to the same level, but that the level indicated
Ly uo oo"r-u,Il assay such as the thrombotest procedure (23) is lower than the levels
found for the individualfactors (13,18).
Recently, we estimated that in steady state anticoagulation the level of any of the
individ.uai factors can be calculated as 2.5 times the percentage found from the
thrombotest assay (15). Other authors, however, have reported a spebific loweringof
one factor relative to the others in long-term treatment with vitamin K antagonists
(28) and it has been postulated that the percentage found from athrombotestassay
indicates this lowest level (24). Since we were unable to confirm this finding (I2, l4),
it appeared that d.ifferent methods of estimation could lead to essentially different
results, even for the level of only one of the clotting factors.
The results of kinetic studies on the clotting reaction occurring with use of the
thrombotest reagent led us to assume that in vitamin K deficiency'an inhibitor of this
reaction must be present (5, 6). It could be shown that the prolongation 9f gloltlnq
time caused by the presence of this inhibitor results in an underestimation of the level
of the clotting factois in the sample, especially when this sample is present in relatively
unfiluted form in the final reaetion mixture. Therefore, this inhibitor had a marked
influence in ihe thrombotest reaction, in which the plasma to be tested constitutes
l0-I5o/o of the final reaction mixture, but was not easily recognized in our assays of
the individual clotting factors, where the plasma to be tested. amounts to orly 2.5o/o
of the final reaction volume (see under Methods). Consequently, the latter tests must
be fairly insensitive to this inhibitor'
It selms Hkely that the discrepancies in the published results were caused by
variations in the influence of the inhibitor depenfing on dilution as well as by possible
variations in sensitivity to this inhibitor inherent to the various specific assays used by
the fifferent authors.
Although we have not yet been able to obtain this inhibitor in a pure state, we
think th;t at, present the kinetic experiments have supplied sufficient evidence to
permit recognition of the postulated inhibitor as a definite entity.
ftrombos. Diathes. haemorrh. (Stuttg.)
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The use of the estimation of the inhibitor as a means of differentiating between
vitamin K deficiency and liver damage in clinical laboratory practice has already
been desoibed (8).
On the basis o{ a hypothesis concerning the synthesis of vitamin K-dependent
clotting factors, we gave the name preprothrombin to this inhibitor in our preliminary
reports. Since there are indications that the inhibitor is related to other vitamin K-
dependent clotting factors and not to factor II, and because other workers have
meanwhile introduced a prethromb'in (I7), the term preprothrombin is apt to be very
confusing. X'or this reason, this term will be replaced here by Protein lnduced by
Zitamin 1l - bsence or ,4ntagonists (PIVKA).
Materials antl Methotls
Ilnless otherwise stated, D'icumarol plasma, indicates a freshly pooled plasma from at least
10 patients under long-term ant'icoagulant treatment and under routine supervision by our throm-
bosis servicel). This plasma was freed of platelets by centrifugation for 20 min at 20,000g in a cooled
super-speed centrifuge (Lourdes betafuge or Servall RC-2b). Normal plasma always indicates a
pooled piatelet-free plasma from at least 30 healthy normals (equal number of males and females,
mean age around 30 years) spun platelet-free (20 min; 20,000 g; 4'C) and stored at -20'C in
1 rnl portions. Ihromboplasti,rz indicates human brain thromboplastin prepared according to Owron
and Aas (22).
Specific reagents used:
Factor II reagent:
a,/ Plasma from a case of severe congenital factor II deficiency, centrifuged and stored as tho
normal plasma pool ; this plasma was kindly supplied by Dr. M. C. Verloop, Ilniversity Hospital,
Utrocht.
b) A mixture of equal parts of oxalated human serum and Barium Sulphate adsorbed bovine
oxalated plasma, prepared according to Loeliger ( 1 1).
Eactor V reo,gelrr'wa,s prepared according to Borchgrevink (3).
Factor V I I reagent was plasma from a case of congenital factor VII deficiency, centrifuged and
stored as t'he normal plasma pool.
Fcr,ctor X reagent was plasma from (a) a congenitally factor X-deficient plasma or (b) plasma from
a patient with an acquired factor X deficiency due to amyloidosis. These plasmas wero kindly
supplied by Dr. M. C. Verloop (University llospital, Utrecht) and Dr. G. den Ottolander (Dijkzigt
Hospital, Rotterdam), respectively.
Fo,ctor VII-X rea,gent was Seitz-filtered oxalated bovine piasma, prepared according to Bach-
mann (1) .
All specific clotting tests were carried out in the same way: 0.1mI reagent, 0.1 ml thrombo-
plastin and 0.1 ml sample diluted 1/ro with Michaelis buffer, were incubated for 30 sec, after which
the reaction was started with 0.1 ml of CaCl, 25 mM.
The moment of clotting was determinod with a Kolle hook, and the time between the cornmenco-
ment of the reaction and the moment of clotting was measured with a chronometer, AII reactions
were carr ied out  at  37'C + 0.05'C.
Tho thrombotest reaction was carried out with 0.25 ml Thrombotest roagent (Nyegaard, Oslo)
to which 0.05 ml of plasma or a plasma dilution was added. The clotting timo was again measured
with a Kolle hook or in the coagulometer (29).
Tho buffer used for dilution was Michaelis buffer pH 7.4.
Dilution (D) will be defined as the ratio of final volume of a plasma sample over its original
volume; t'herefore, undiluted plasma had a dilution factor of unity (D : 1).D : x means that
x- 1 volumes of diluent were added to one volume of plasma.
A t-D piot is a plot in which the clotting time (t") obtained with plasma at a known dilution
(D) is plotted along the Y-axis and the dilution along the X-axis. When the term "clotting factor
1) The large majority of those patients was treatod either with phenprocoumon or with aceno-
coumarin.
348
concentration" is used in this context, we mean the concentration of the clotting factor that is
rate-limiting in these clotting time estimations. Usually, this will be factor X (9). The concen-
tration is expressed, as usual, as a percentage of the concentration in the normal plasma. In the
t-D plots shown here, each point represents the mean of at least 16 determinations.
T heor eti, cal C ons'id,er ati on s
In a previous article (9) we have shown that the t-D plot obtained with a dilution
of normal plasma in the thrombotest reagent is a straight line.
Furthermore, it was demonstrated in that article that unless the level of factor II or
factor VII is significantly lower than the level of factor X, the clotting time obtained
with the thrombotest reagent is determined by the level of factor X. This held regard-
less of whether the sample was diluted or undiluted.
In both chroni,c liver disease and prolonged vitamin K deficiency, factors VII and II
are known not to show any tendency to drop below the level of factor X (L2, I4).
Therefore, the graph obtained in a t-D plot estimation with thrombotest may for all
practical purposes be regarded as an experiment in which the dilution of lactor X is
plotted against the clotting time.
A t-D line shows two features of special importance : the slope of the line (a; expressed
as the cotangent o{ the angle between this line and the abcissa) and the intercept of the
line with the ordinate. This intercept indicates a point on the clotting time axis and
therefore a clotting time, calledm'in'imal clotting time (t'.,i..).
We have already shown (7) that the ratio of the slope (a") obtained with any given
plasma to the slope (a1) obtained with normal plasma indicates the amount of rate-
limiting clotting factor (i. e. factor X) in the unknown plasma. In the following pages,
an will be arbitrarily considered to equal 100; a; then directly indicates the level of
factor Xin o/o.
The physical meaning of t6ir1 is that this is the shortest clotting time obtainable by
increasing the concentration of factor X. By extrapolation, we get t-in as the clotting
time at infinite lactor X concentration and at a level of factors II and VII that repre-
sents an excess of these factors. This means that all plasmas differing only in their
factor X content should have the same tmin, because the factor X level is of no im-
portance once the extrapolation to infinite factor X concentration has been carried out.
Since it has been shown that levels of factors II and VII equal to or higher than the
level of factor X represent an excess of reactants, this statement can be extended to:
AII plasmas with different factor X contents and with factor II and factor VII
contents not significantly lower than their factor X level, have a tmin that is equal to
the t*i,' of normal plasma, provided no modifiers of the reaction are present.
Under modifiers we understand here substances that have a specific influence on the
reaction but that are not taken account in the above reasoning. Both accelerators and
inhibitors fall into this category.
Ionic strength, pH, temperature, Ca++ ion concentration, etc. may also be regarded
as modifiers of the reaction rate. Their influence is nesated when estimations are
performed under controlled conditions.
Experimental Results
X'ig. 1 shows a t-D plot of a pooled plasma of 12 patients with chronic liver disease.
Fig.2 shows a t-D plot of a pooled. plasma of 12 patients under prolonged anti-
coagulant treatment.
It is obvious that the minimal clotting time obtained with the Dicumarol plasma
is markedly higher than that of normal plasma, whereas the minimal time of cirrhosis
t
|  1s0
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Fig,l. Thromhotest time-d'i'lutdon plot oJ cimhos'is plasma. O-a -tDplot of normal plasma;
O- O t -D plot of a pooled plasma of 12 patients with chronic hepatic cirrhosis. t*i1 of both
plasmas in 39 sec. The relation of tho slopes of the two lines (cr) indicates a factor X contant of 40!o
for the cirrhosis plasma. For the cirrhosis plasma, I : 0.
Fig.2. Thrombotest-di'l'ution plot oJ Dicumarol, ltlasnta. O-a t-D plof of normal plasma.
O-O t-D plot of Dicumarol plasma. t6o of normal plasma is 89 sec, f_i1 of Dicumarol
plasma is 70 sec. Tho relation of tho slopes (a) indicates a factor X level of 22/o in the Dicumarol
plasma. I : 1.6.
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plasma is equal to that of normal plasma. Furthermore the value I will be mentioned
in the legends to the figures,'I being defined as the length of a horizontal line between
tr6,' of normal plasma on the Y- axis and the intercept of this horizontal line with the
t-D line of the experimental plasma expressed in the units of length of the X (-dilution)
axis. I is represented graphically in the figures by a dashed line. I is said to be positive
when the intercept of the horizontal line and the t-D line lies to the left of the Y- axis.
It will be shown later that the length of I indicates the amount of the postulated
inhibitor.
X'ig. 3 shows that the prolongation of t6n must be regarded as a result of vitamin K
deficiency rather than as an effect of the presence of circulating Dicumarol; essentially
the same results are obtained under anticoagulant treatment and in absolute vitamin K
deficiency due to proven resorption defects. Figs.4 and 5 show that addition of cirr-
hosis plasma to Dicumarol plasma or vitamin K deficient plasma tends to lower the
thrombotest times and therefore the tmin of the latter two plasmas. This is the case
even though the cirrhosis plasma shows slightly lower levels of factors II, VII, IX,
and X in the specific test (Table 1). n'ig.6 shows that Dicumarol and vitaminK
deficient plasmas do not correct each other's prolongation of t-io because t-ir of the
mixture is not lower than the mean of the t161's of the individual plasmas.
Fig.!, Thrombotest-d,iluti'on ptrot oJ Ttlasma oJ adtamin K-def'c'ient pa,ti,ents. O-O t-D plot of
normal plasma; O-O t-D plot of pooled plasmas of 7 vitamin I(-deficient patients. t-ir of
normal plasma is 39 sec; t^i, of vitamin l(-deficient plasmas of 67 sec. The relation of the slopes
indicates a factor X level of.24o/o in the vitamin K-deficient plasma. I : 1.6.
A frequency distribution curve of the value of I in hepatic disorders, Dicumarol
treatment, and vitamin K deficiency is shown in X'igs.7, 8, and 9. These figures clearly
show that prolongation of t-i,' and therefore a positive value of I is a feature of
absolute as well as drug-induced (relative) vitamin K deficiency.
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Fig.4. Thrombotest-d,i,luti,on plot oJ a mirture oJ cirrhosi,s pl,asma and, Dicwmd,rol, pl,asnxa. O-O
t-Dplotof normalplasma; Q-e FDplotof cirrhosisplasma; A-A FDplotof Diou-
marol plasma. O- O t--D plot of a mixture of equal parts of cirrhosis plasma and Dicumarol
plasma. X'or the values of tmin, a, and I, see Table 1.
t
t 'c
(sec.)
Fig.5. Tlwombotest-d,'ilution plot of a rn'intwre oJ cilrhosi,s Ttlasma amil, tsi,tamim-K d,ef,cdent plasma.
O-a t-D plot of normal plasma; e-e t-D plot of cirrhosisplasma; 8-8 t-D
plot of vitamin Ii-deficient plasma; O-O t-D plot of a mixture of equal parts of cirrhosis
plasma and vitamin K-.deficiont plasma. X'or the valuos of tmin, a, and I, see Tablo 1.
3 1 5 6 7
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Table 1. Tho Level of X'actor II, Vf|, and X and tho Values of a, t*i1, and I of tho Plasmas
' 
Shown in Figs. 4, 5, and 6.
Plasma F. II x'. vl F . X u umln I
Normal
Dicumarol
Vitamin K-def.
Cirrhosis
Dic./vit. K-def.
Dic./cirrh.
Vit. K-def./cirrh.
100
34
22
30
28
34
29
100
30
23
0 a
23
27
25
100
28
23
22
o a
24
24
100
30
26
22
,9,
26
25
39
59
66
39
62
5 L
54
0
L 4
1.6
0
1.5
0 .7
0.8
Tig.6. Thrombotest-di,luti,on plot of a nt,irture oJ Di,cumarol plasma amd, o'itamim K-d'ef'cient plasrna.
a- O t-D plot of normal plasma ; A- I t-D plot of Dicumarol plasma' e-e t_D
plot of vitamin K-deficient plasma; O-O t-D plot of a mixture of equal parts of Dicumarol
plasma and vitamin l(-deffcient plasma. X'or the values of tmin, a, and f, seo Tablo 1.
n'ig. 10 shows the t-D lines of pooled plasma of patients on different levels of long-
term anticoagulant treatment. n'ig. 11 shows the t--D plot of mixtures of AI(OH)B-
adsorbed Dicumarol or cirrhosis plasma and normal plasma.
Table 2 shows the behaviour of the t-D plot of Dicumarol plasma after various
treatments, and illustrates the absence of the inhibitor in serum. Fig. 12 shows the
effect of adfing a fixed. amount of Dicumarol plasma in an experimental situation
when the concentration of the factors II, VII, and X is varied independently of the
amount of Dicumarol plasma. This was done by taking the plasma (called plasma A),
of an anticoagulated patient (factor II: 10o/o; factor VII: 9o/o; faatot X: l0o/o;
factor IX: tlo/o;T:2.0) and. treating a portion of it with AI(OH)3, after which all
factors were absent, as IMeII as the inhibitor, as can be judged from a similar experi-
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Table 2. The fnfluence of Various Tregtments of Dicumarol Plasma on the Parameters of itsi
Thrombotest-Dilution Curve.
No. Description
Clottir
r l v
rg factors (o/e)
t l
Ylr - lor t  |  *+^ l  I
t-D plot
" lr
A Normalplasma
B Dicumarol plasma
C B after adsorption onto Al(OH),
D EqualpartsofAandC
E Equal parts of B and C
F B af terheat ing4hat 45'  C
G B after dialysis 24 h at 4o C against
Michaelis buffer
II Dicumarol serum
f EqualpartsofAandl l
100
rc
0
45
7
10
15
2
60
100
It5
100
100
100
10
n q
L
48
100
1 8
0
54
8
t2
14
120
1 1 5
100
1 6
0
52
I
t2
L5
150
120
100
1 8
0
50
I
14
l5
90
98
100
L7
50
I
1 3
L 6
93
0
1.5
0
0.8
0 . 1
7 . 1
n 9 .
Adsorption with BaSOn or Car(POn), gave essentially the samo results as adsorption with
AI(OH), providod that oxalated plasma was usod.
Fig.7. X'requency distribution diagram of tho value of I in patients with chronic hopatitis as
compared to normals. Tho values found in 25 patients are compared with tho values for:ld in
31 normals.
hepat i  s
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X'ig.8, X'requency distribution diagram of the value of I in patients under 'Dicumarol' treat'ment.
The values fould in 27 patients are compared with the values found in 31 normals.
ment shown in Table 2. To 9 palts of the adsorbed plasma, 1 part of nolmal plasma
was added. The resulting mixture (plasma B) showed the following features: factorll:
tTo/o; factor VII: 10"/"; factor X: 9o/o; factor IX: 10o/o; I: 0.0. With respect to the
content of the clotting factors, plasma B was comparable to plasma A; but, the value
0.0 for I indicates that t6i' was equal to that of normal plasma and thus that this
plasma did not contain the postulated inhibitor. A series of dilutions of normal plasma
was then made, and to each of these dilutions an equal volume of either plasma A or
plasma B was added. By this procedure the clotting factor level of a dilution of normal
plu.ma (say Do/o) became t/r(D + 10)o/". The only difference between the addition
of plasmu A or plasma B rnzas that the postulated inhibitor was added with A, but not
*itn g. Since the amount of plasma A was the same in all dilutions made, the amount
of inhibitor added was also the same. It should be noted that n'ig. 10 is not a t-D plot
but is closely analogous to the classical Lineweaver-Burk plot of enzyrne kinetics. The
fact that the two lines in this graph intercept at the ordinate, indicates here that at
infinite substrate concentration a finite inhibitor concentration does not influence the
reaction rate.
Fig. 13 shows the t-D curve produced when a non-competitive inhibitor is present,
in the plasma, in this case fibrinogen breakdown products. X'ig. 14 shows a L-D curve
of plasma from a patient with cirrhosis of the liver who was on anticoagulant therapy.
JDO
X'ig.9. Frequoncy distribution diagram of the value of I in patients with proven vitamin K-
deficioncy. The values found in 18 patients are compared with the values found in 31 normals.
In I'ig. 15 experiments are displayed. in which the thrombotest-time and the fac-
tor X concentration were estimated and compared. The thrombotest-time was plotted.
against the inverse of the factor X concentration of the same plasma. Two groups of
plasmas were tested, firstly a series of mixtures of normal plasma and BaSOn adsorbed
plasma (lower lines), secondly plasmas of different patients on different levels of anti-
coagulant treatment (upper lines)
It is seen thaL at' the same concentration of factor X the thrombotest-time in
Dicumarol plasma is always higher than in (diluted) normal plasma. At infinite fac-
tor X eoncentration (i. e. at the Y-axis) the difference between normal and Dicumarol
plasma is no longer found, again indicating the presence of a fixed amount of a com-
potitive inhibitor in the Dicumarol plasma.
Discussion
The curves shown in X'igs. I, 2,3,7, 8, and 9 indicate that the two parameters of
the t-D tine (i. e. slope and tmin) vary in vitamin K deficiency but that only one para-
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X'ig. 10. Thromhotest-d,i,luti,on plot oJ pla,emas oJ patients on d,i.fferent leoels oJ long-term anti,coagulant
trearment. O- O t-D plot of normal plasma; e-e t-D plot of a mixed plasma of 15 low-
level anti-coagulated patients; O-O t-D plot of a mixed plasma of 15 modium-lovel anti-
coagulated patients. A-8 t-D plot of a mixed plasma of 30 highJovel anti-coagulated
patients.
Lovel of anticoagulation r'. II F. VIII F . X d + .utlln I
Low
Medium
High
47
32
12
5U
30
I D
42
27
1 3
46
3 1
1 6
DU
62
83
1,6
t ,6
1 ,6
meter (i. e. slope) varies in chronic liver disease. A marked elevation of t6i' is seen
onlyin absolute or drug induced vitamin K deficiency.
It appears to make no difference whether the vitamin K deficiency is induced by
drugs or caused by defective absorption (X'ig.6). The ehanges seem to be quantitatively
related to the amount of vitamin K-deficient plasma present (X'igs.4 and 5).
In accordance with the conclusion drawn in our theoretical considerations above,
the change in t6ir1 must be due to the presence or absence of a modifier. This modifier
cannot be one of the known clotting factors, since "t*i' is a clotting time at infinite
factor X concentration and factors II and VII have been shown not to be rate-
limiting in this situation (9), factor IX does not influence the thrombotest time, and
no other known clotting factors are affected. by vitamin K deficiency. This leaves us
with four possibilities :
a) an abnormal procoagulant is present in chronic liver disease but not in vitamin K
deficiency;
b) a normal inhibitor is absent in chronic liver disease but present in vitamin K
deficiency; (N. B. This coald not be Antithrombin 3 because this inhibitor is present in
excess in the Thrombotest reagent.)
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X'ig. 11. Tkrombotest-timed,i,lutionplotoJam,irtureoJnormalanilAI(OH)uad,sorbed,D,icumarolplasmo
orcirrhos'i6plasnxa.a-a t-Dplotof anormalplasma; a-| (uppercurve)t-Dplotof
a, mixturo of AI(OH)r-adsorbed cirrhosis plasma, (7 parts) and normal plasma (3 parts). A-a
t--D plot of a mixture of 3 parts normal plasma and 7 parts A1(IIO)r-adsorbed Dicumarol plasma.
f
| 1s0
+
(sec.)
Fig. L2. Plot oJ Thron'ftotest-t'ime against the inuerse oJ cl,ot?ing-Jactor ooncentrat'i,on in the presemce amd,
a,bsemce of a f,red, anLount oJ Ddcuma,rol plasma, Explanation in text.
4 5 6 7
2 1 6 8 1 0  1 2  1 t 1 6 ' t 8
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t 1s0
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t c
(sec.)
100
1 2 3 1 5 6 7
Fig. 13. llhrombotast-t/i,me diluti,om ptrot in the presence of a non-competit'iae inhibi'tor. a-a
normal plasma ; O-O pathological plasma.
COUMARIN TREATMENT
IN CHRONIC HEPAIITIS
T  ( scc )
200
'/r t/t 7e
X'ig. 14. Thrombotest-time ililution in plot after 'Dicumarol' admi,mi,atra,ti,on'in a case oJ liaer cirrhosis.
5 6 7
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corretat ion curve acc. to OWREN)
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Fig, 15. Relation betweem factor X concentretiorl and, thrombotest-ti.me in Dicumarol pl,asmas Jrom,
il,i'frerent patdents. The reciprocal of factor X concontration (X axis) is plotted against thrombotest-
time (Y axis) obtained with the samo plasma. Each dot represents values obtaned with plasma of a
different patient. The two parallel lower linos indicate tlne 85o/o confidenco limits of the same data
obtained with dilutions of a normal standard plasma with Al(oH)s-adsorbod plasma.
c) a normal procoagulant is absent in vitamin K deficieney but not in chronic liver
disease:
d ) an abnormal inhibitor is present in vitamin K deficiency but absent in chronic
liver disease.
Possibilities a) and b) are rendered unlikely by the observation that t-;1of cirrhosis
plasma is equal to but not lower than that of normal plasma. Possibility a) is even
more unlikely because it is known that chronic liver disease tends to cause depletion
of plasma constituents synthesized by the liver rather than to result in the production
of new ones.
The same reasoning makes possibility c) unlikely, since it is hard to imagine that
vitamin K deficiency would affect more functions of t-he liver than does chronic
ciruhosis.
_ 
The argument is settled by the experiments whose results are shown in Fig. 11.
Removal of a substance from Dicumarol plasma by adsorption on AI(OH), returns
to normal the t*itr of the mixture containing Dicumarol plasma whereas it has no
influence on trnin of the mixture containing cirrhosis plasma. This proves the presence
of an anticoagulant in Dicumarol plasma that is adsorbed by Al(OH)r.
X'ig. 12 shows that the inhibitory substance present in Dicirmarol plasma behaves
as a competitive inhibitor: at infinite substrate concentration (i. e. at the Y-axis)
the presence of a f,ued, amount of inhibitor has no influence on the clotting time.
INHIBITOR PRESENT
vatues found in pat ients
treated wi th coumarin
360
Table 2 shows that, the inhibitor has a large molecular weight, is heat labile; and
is BaSOu, Al(OH)s- and Car(I'Ou)r-adsorbable; thus presumably is a protein. Ifence-
forth we will call this substance Protein lnduced by Zitamin K,4bsence or Ant'a-
gonists (PIVKA).
As will be proven in the article to follow, the quantity of a competitive inhibitor
present in the undiluted plasma sample is proportional to the disbance on a horizontal
line between tmin. uninh. and the intercept of the t-D line of the experimental plasma
with that horizontal line. This distance - called I - is expressed in units, 1 unit being
defined as the distance between D : 0 and D - L at the X-axis. I is said to be
positive when the intercept between the horizontal line and the t-D plot lies to the
left of the ordinate.
A plasma is defined as containing 1 u of inhibitor when the I measured in the t-D
graph of this plasma amounts to 1 u of length. X'ig. 10 shows that all persons with
healthy livers tend to have the same level of PI\IKA when on long-term treatment
with a vitamin K antagonist, independent of the level of anticoagulation. Our con-
clusions from the experimental results reproted in X'ig.10 are supported by indepen-
dent evidence from the experiments shown in n'ig. 15.
In these experiments the plasmas of patients on different levels of anticoagulant
treatment provide material with different concentrations of factor X but with an
amount of PIVKA that tends to scatter around a constant mean, independent of the
level of factor X.
The method used to plot the data in Fig. 15 thus again results in an analogue of a
Lineweaver-Burk plot, and again suggests strongly that PIVKA is a competitive
inhibitor of a reaction involving factor X.
n'ig. 14 shows an observation concerning accidental Dicumarol administration in a
case of liver cirrhosis. This result suggests that in this case there was hardly any
synthesis of the inhibitor, which might be a first indication that PIVKA is synthesized
in the liver. The adsorption charaeteristics inficate a protein that has much in
common with the clotting factors of the so-called "prothrombin complex" i. e. the
clotting factors II, VII, IX, and X (Table 2). The fact that we deal with a competitive
inhibitor of thrombin formation suggests that the substance may be a substrate
analogue of one or more of the clotting factors II, VII, IX, or X. This again suggests
a protein closely resembling one or more of these factors. In view of the known
difficulties of separating the prothrombin complex into its constituent factors (2, 30),
it is not surprising to see that it is possible to achieve a considerable purification of
the inhibitor relative to plasma proteins but that it is difficult to separate it from
the factors of the prothrombin complex. Extensive column chromatographic ex-
periments are being carried out in our laboratory at present, (J. M. C. Wimmers and
A. C. W. Swart) they occasionally show fractions with an inhibitory action only. The
identity of this protein and the inhibitor postulated here has not yet been confirmed,
however. Nevertheless, we think that the kinetical approach described here yields
enough evidence to recognize PIVKA as a distinct entity. The question of why vitamin
K deficiency would induce the synthesis of an inhibitor cannot be solved at the mo-
ment, but the known facts provide a basis for the construction of a hypothesis which
can serve as a rewarfing tool for the design of further experiments.
The following facts are to be recognized:
a) There is no known influence of vitamin K upon protein synthesis as such (25);
b) A specific influence of vitamin K on the protein synthesis of some clotting factors
has been suggested (20). However, a close examination of these experiments shows
that they do not present any fiscrepancies with the hypothesis put forward here (21);
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c) The factors of the prothrombin complex are known to be conjugated" proteins
containing up Lo 50o/o non-protein material, mostly sugars (16,26, St ); 
-
d) Glycoproteins are synthesized in two steps; the protein moiety is procluced, first
and then the sugars are attached (4, Ig\;
e) The blood level of the vitamin K dependent clotting factors is kept constant by
the activity of liver cells;
f) PIVKA is a protein with a close resemblance to the factors of the prothrombin
complex and appears to be synthesized by the liver;
g) Vitamin K is not a constituent of the clotting factors (27).
Points a), b), c), and d) suggest that the factbrs of the prothrombin complex are
synthesized in a two-step procedure. First, a protein moiely is made and tlen this
moiety is converted into a conjugated protein. The data in the literature suggest that
vitamin K works upon the second step rather than upon the first on". W" do not
know what comprises the second step, but as an illustration we shall assume that it
consists of the conversion of a protein into a glycoprotein. The structural similarities
a_nd pharmacological behaviour of vitamin K and drugs of the cumarol group suggest
that vitamin K is a coenzyme in a system that catalyses this protein -------- gIy"o-
protein conversion. This leads to the following scheme of coagulation factor synihesis
in the liver cells:
genetically- controlled
protein s;mthesis
vitamin K-sensitive
errzyme system
amrno acrds -------------- --> protein ____ _> clotting factor
The fact that the clotting factor concentration in the plasma is maintained at a
constant.level suggests a feedback system in which the level of a clotting factor
controls its synthesis rate. The controlled rate could be the rate of either the first or
tho second step. If the rate of the first step were under the control of this feedback
mechanism inhibition in the second step would cause maximal svnthesis in the first
step. The product of this first step, would only be converted into the clotting factor
slowly because of the inhibition of the second step. This would lead, to piling up of the
intermediate product. If this product rnras able to reach the circulatio.r, its p""."trce
there would explain the observed facts, since the intermediate product is a protein
much like the final clotting factor synthesized by the liver. It therefore coold -r""y
well be a substrate analogue of one of the clotting factors and thereby an inhibitor.
The constant level found for steady-state anticoagulation in patients with a healthy
liver represents a maximal s;znthesis rate in the first step combined with a steadv
low rate of conversion in the second step. Isolation of tle inhibitor would. offer L
uqq]re opportunity for the study of the vitamin K-dependenL enzyme system in liver
cell fractions.
Summary
Application of enzyme kinetics to the results of thrombotest estimations in correla-
tion with specific clotting factor estimations has led to the recognition of a protein
m9i9ty that occurs in plasma in vitamin K defieiency and acti as a comp-etitive
inhibitor of thrombin formation. A hypothesis is given by which the occurrence of
this inhibitor is explained in terms of a biphasic synthesis of the vitamin K-dependent
clottins factors.
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R6sum6
La th6orie de la cin6tique enzymatique appliqu6e aux r6sultats de I'estimation du
Thrombotest en corr6lation avec I'estimation sp6cifique des facteurs de Ia coagulation
conduit ir, la reconnaissance d.'une prot6ine plasmatique dans les cas de d6ficiences en
vitamine K, qui agit comme un inhibiteur comp6titif d.e Ia formation de la throm-
bine. Une hypothdse est 6mise suivant laquelle I'apparition de cet inhibiteur serait
expliqu6e pur tu synthdse en 2 temps des facteurs de la coagulation d6pendant do Ia
vitamine K.
Zusammenfassung
Die Anwendung von Enzy'mkinetik auf fie Ergebnisse der Thrombotestbestim-
mungen in Bezieiung mit spezifischen Gerinnungsfaktorbelt]mmung_9n_ hat zu der
Erke-nnung eines Eiiei8stoffes gefiihrt, der im Plasma bei Vitamin-K-Mangel vor-
kommt otid 
"l* 
ein kompetitivJr Hemmstoff der Thrombinbildung wirkt. Es wird
eine Hypothese aufgestellt, welche das Auftreten dieses Ilemmstoffes in n'orm einer
2-phasis-chen Synthese der Vitamin-K-abhiingigen Gerinnungsfaktoren erkliirt.
Acknowl'ed,gements
This work could not havo been accomplishod without the invaluable technical assistance of
Miss Else Alsbach and Mrs. W. van Neerbosch -W}'nia. Part of this work has been carried out under
the auspices of the Notherlands Foundation for Chemical Resoa,rch (S.O.N.) and with financial
aid from tho Notherlands orqanisation for tho Advancemont of Pure Research (2.w. o.)'
References
(ll Bachm,ann,E., LDuckert, F.Koller: The Stuart-Prower factor assay and its clinical signif-
icance. Thrombos. Diathes. haomonh. (Stuttg.) 2: 24 (1958).
(2) Bi,ggs,,R..' The point of view of the individual as a scientiffc author. Thrombos. Diathes.
haomorrh. (Stuttg.) 1,5; 603 (1966).
(B) Borahgreadnk, C. 8., J. G. Pool, H. Stormorkem.'A new assay for Factor V (Proaccelerin'
accelerin) using Russell's vipor venom. J. Lab. clin. Med. 55: 625 (1960)'
(4)  Cook,G.M. 'W.,M.T.Lai ,co,E.A.Eglar :  Biosl 'nthesisof  g lycoproteins.of  theEhr l ichasci t is
carcinoma cell membranos. Proc. Nat. Acad. Sci. 54:247 (1965).
(5\ Hemker, H. c., J. J. Vettkam,p, A. Een^sem, E. A. Loeli,ger; on the nature of prothrombip
biosl'nthesis. Naturo (Lond.) 200: 589 (t963).
(6\ Hentker,Il. C.; Preprothrombin (Complex ?), a circulating anticoagulant in coumarin treated
and vitamin K deffcisnt patients. Thrombos. Diathes. haemorrh. (Stuttg.), Suppl' 13; 380
(  1e64 ) .
(7) Henzker, H. C., P. W. Hernker, E. A. Loeti,ger.'Kinetic a,spects of tho interaction of blood
clotting enzJftnos. f. Derivation of formulas. Thrombop. Diathes. haemorrh. (Stuttg.) 13: I55
( '1965).
(8) Hem,ker,H.C.,J.tsamd,erMeer,E.A.Loel,iger:Differenti6leleverfunctiobepalingmetbehulp
van de thrombotost van Owren. Ned. T. Goneeskunde 109: 646 (1965).
(9) Hemker, H, C., ll. v. Bi,epel, R. Attman, E. A. Loel,'iger.'Kinetic aspects of the interaction of
blood clotting onzymes. II. The rolation botween clotting time and plasma concontration in
orothrombin-time estimations. Thrombos. Diathos. haemorrh. (stuttg.) 17:349 (1967)'
(lO) Loeli,ger, E, A.: TJber don Nachwois eines neuon Gerinnungsfaktors: Faktor VII. Thesis.
WielnZ, inn. Mod. 33: L69 (L952).
(ll\ Loeli,ger, E. A., F. Roller: Boha,viour of factor YII and prothrombin during late pregrrancy
and in the newborn. Acta haemat. (Basel) 7: L57 (1962).
363
(I2) Loetiger, E. A., B. aan iler Esch, M. J. Mattern, A. B. A. dnn Bra,bamd,er.'Behavior:r of fac-
tors If, VII, fX, and X during lirng-term treatment with courqarin. Thrombos. Diathes.
haemorrh. (Stuttg.) I : 7 4 (1963).
(t3) Loel'iger, E. A., A. Hensen: Grundlagon erfolgversprechender Langzeitbehandlung rnit
Coumarin. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl. 12: 111 (1964).
(14\ Loel,iger, E. 4., A. Hemsen, M. J. Mattern, H. C. Hernker: Factors II, VIr, IX, and X in
bleeding complications during long-terrntroatrnont with coumarin. Thrombos. Diathes.
haemorrh. (Stuttg.) 10 : 27 8 (1964).
(I5) Loel,iger, E. 4., A. Hemtam, E. Kroes, L. M. uan Dijk, N. Fekkea, H. C. Hem,ker.' A double-
blind study of phenprocoumon prophylaxis in coronary heart diseaso. Acta med. Scand. -282.'
549  (1967 ) .
(L6) Ma,gnusson, S..' Proparation and carbohydrate analysis of bovine prothrombin. Arkiv f6i
Kerni  23:285 (1965).
(17) Marcini,ak,E.,W.H.Seegers:Prethrombinasanewsubunitofpiothrombin.Nature(Lond.)
209:621 (1966).
(I8) Matthews, J. M., W. Wa,Ilcer: Control of anf,icoagulant thorapy. A trial of. thrombotest.
Lancet  I I ,  1159 (1959).
(L9) Molnar, J., G. B. Robi'nson, R. J. Winzl'er.'Biosy'nthosis of Glycoproteins. IV. The sub-
cellular sites of incorporation of glucosamino -1-1aC into glycoprotein in rat livor. J. biol.
C}rern. 2 <10 : 1882 (1965).
(20) Olson, R. .8..'Vitamin I( inducod prothrombin formation antagonism by Actinomyoin D.
Science 145 : 926 (1964).
(2 1) Ol,s on, R. .E..' Personal communication 1 966.
(22) Otnen, P. A., K. Aas: TIrc control of Dicumarol thorapy and tho quantitativo dotormination
of prothrombin and proconvertin. Scand. J. clin. Lab. Invest. 3.' 169 (1951).
(23) Otnren, P. .4.: Thrombotest, a now method for controlling anticoagulant thorapy. Lancob II,
754 (1955).
(24) Ounen, P. -4..' Tests for control of anticoagulant therapy. Thrombos. Diathes. haemorrh.
(Stuttg.) Suppl. -13; 369 (1964).
(25) Proc. Symp. on recenf advances in resoarch on vitamins I( and related Quinones, Vitamins
and Horrnones Yol.24.
(26) Prgd,z, If..' Some charactoristics of purified Factor YII preparations. Scand. J. clin. Lab.
Invest. J7, Suppl. 84:78 (1965).
(27) Ray, G. C., N. N. Chukrauarty, S. C. Rag: Prothrombin and its relation to vitamin K. Ann.
biochom. exp. Med. (Calcutta) 22:3L7 (1962).
(28) Shanberge, J. N.: Tho offect of Dicumarol on certain factors in blood coagulation. J. Lab. clin.
M e d . 4 8 ; 2 1 8  ( 1 9 5 6 ) .
(29) Sohn'itger, H., R. Gross.'tlber ein llniversalgeret zur automatischen Registribrung von Ge-
rinnungszeiton. Klin. Wschr. 1954: l0ll.
(30) Seegers, W. H.: Proltnombin. Ilarvard Ilniversity Pross, Cambridgo 1962.
(31) Ti,shlrcff,G. H., L. Peohet, B. Alenand,er: Somo biochomical and electrophorotic studies on
purified prothrombin, X'actor VIi and Factor X. Blood 15; 778 (1960).
Received for publication July 25,1967
Qopy,righ.r,!1 F. K. Sdrattauer-Verlag, Stuttgart - Der Verlag behllt si& alle Redrte, besonders die des Nachdru&es,der vervreltaltrgung und der ubersetzung vor.
